Genes & biomarkers

NTRK1 / NTRK2 / NTRK3 fusions

NTRK1 / NTRK2 / NTRK3 · TRK fusion

An NTRK fusion can guide treatment beyond the organ where a cancer started.

Sources checked · Introductory guide

On this page

What does this result mean?

An NTRK fusion joins an NTRK gene to another gene. It is different from a point variant, amplification or a note that NTRK testing was performed.[1]

How does it connect to treatment?

TRK inhibitors such as larotrectinib are considered for selected NTRK fusion solid tumors. Operability, spread, previous treatment or alternatives and known resistance variants also matter.[2]

What should I check in my report?

Ask which NTRK gene and fusion partner were found and whether the finding qualifies for treatment. A gene name in a variant list is insufficient.

Questions for your care team

  • Does my fusion meet the criteria for a TRK inhibitor?
  • Which treatments or trials fit my cancer type, stage and previous treatment?

Sources and scope

Source documents are in English.

Entries summarize and translate linked official public sources. The source-check date records when those sources were checked; it does not indicate a clinician’s review.

  1. NCI · Larotrectinib (opens in a new tab)
  2. NCI · Entrectinib (opens in a new tab)

General information based on official public sources. This is not a complete list of uses or side effects. Individual treatment decisions require your care team and current source documents. US-source uses do not establish local approval or reimbursement.

Related entries

NTRK1 / NTRK2 / NTRK3 fusions | Cancer Encyclopedia | My Chemo Diary